JP2014524472A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524472A5 JP2014524472A5 JP2014527238A JP2014527238A JP2014524472A5 JP 2014524472 A5 JP2014524472 A5 JP 2014524472A5 JP 2014527238 A JP2014527238 A JP 2014527238A JP 2014527238 A JP2014527238 A JP 2014527238A JP 2014524472 A5 JP2014524472 A5 JP 2014524472A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- heteroalkyl
- tautomer
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 -alkyl-OH Chemical group 0.000 claims 55
- 125000000217 alkyl group Chemical group 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims 33
- 125000001188 haloalkyl group Chemical group 0.000 claims 31
- 125000004404 heteroalkyl group Chemical group 0.000 claims 29
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 150000002367 halogens Chemical class 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 16
- 125000000304 alkynyl group Chemical group 0.000 claims 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000003342 alkenyl group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000004438 haloalkoxy group Chemical group 0.000 claims 10
- 208000024827 Alzheimer disease Diseases 0.000 claims 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 6
- 208000018737 Parkinson disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000002541 furyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000002971 oxazolyl group Chemical group 0.000 claims 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims 5
- 125000004076 pyridyl group Chemical group 0.000 claims 5
- 229940044551 receptor antagonist Drugs 0.000 claims 5
- 239000002464 receptor antagonist Substances 0.000 claims 5
- 125000000335 thiazolyl group Chemical group 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 201000010374 Down Syndrome Diseases 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 4
- 230000006735 deficit Effects 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 208000000044 Amnesia Diseases 0.000 claims 3
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 208000026139 Memory disease Diseases 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 239000003529 anticholesteremic agent Substances 0.000 claims 3
- 229940127226 anticholesterol agent Drugs 0.000 claims 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 230000006984 memory degeneration Effects 0.000 claims 3
- 208000023060 memory loss Diseases 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 claims 2
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 claims 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940125753 fibrate Drugs 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 229960003512 nicotinic acid Drugs 0.000 claims 2
- 235000001968 nicotinic acid Nutrition 0.000 claims 2
- 239000011664 nicotinic acid Substances 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003367 polycyclic group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 125000005493 quinolyl group Chemical group 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 claims 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical group C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 claims 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical group C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical group C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 1
- 108091005435 5-HT6 receptors Proteins 0.000 claims 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims 1
- 102100033047 G-protein coupled receptor 3 Human genes 0.000 claims 1
- 108091007911 GSKs Proteins 0.000 claims 1
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 206010070476 Haemodialysis complication Diseases 0.000 claims 1
- 101000871088 Homo sapiens G-protein coupled receptor 3 Proteins 0.000 claims 1
- 102100023915 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 1
- 102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 claims 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 claims 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 claims 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 1
- 206010056677 Nerve degeneration Diseases 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- 102100024448 Prostaglandin E2 receptor EP2 subtype Human genes 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 229940122777 Tau aggregation inhibitor Drugs 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 150000005215 alkyl ethers Chemical class 0.000 claims 1
- 230000006933 amyloid-beta aggregation Effects 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- 239000003540 gamma secretase inhibitor Substances 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 239000003324 growth hormone secretagogue Substances 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 125000005945 imidazopyridyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 229940127592 mGluR2/3 antagonist Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010014719 metabotropic glutamate receptor type 1 Proteins 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000007388 microgliosis Effects 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000002469 receptor inverse agonist Substances 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 208000008864 scrapie Diseases 0.000 claims 1
- 239000000387 serotonin 5-HT4 receptor agonist Substances 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940124648 γ-Secretase Modulator Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161526049P | 2011-08-22 | 2011-08-22 | |
| US61/526,049 | 2011-08-22 | ||
| PCT/US2012/051687 WO2013028670A1 (en) | 2011-08-22 | 2012-08-21 | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014524472A JP2014524472A (ja) | 2014-09-22 |
| JP2014524472A5 true JP2014524472A5 (enExample) | 2015-10-15 |
Family
ID=47746812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527238A Pending JP2014524472A (ja) | 2011-08-22 | 2012-08-21 | Ｂａｃｅ阻害剤としての２−スピロ置換イミノチアジンならびにそのモノオキシドおよびジオキシド、組成物、ならびにそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9181236B2 (enExample) |
| EP (1) | EP2747769B1 (enExample) |
| JP (1) | JP2014524472A (enExample) |
| KR (1) | KR20140054295A (enExample) |
| CN (1) | CN103874496A (enExample) |
| AU (1) | AU2012298983A1 (enExample) |
| BR (1) | BR112014004181A2 (enExample) |
| CA (1) | CA2844988A1 (enExample) |
| MX (1) | MX2014002113A (enExample) |
| RU (1) | RU2014111055A (enExample) |
| WO (1) | WO2013028670A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA108363C2 (uk) * | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| KR20140054295A (ko) | 2011-08-22 | 2014-05-08 | 머크 샤프 앤드 돔 코포레이션 | Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도 |
| EA201491967A1 (ru) | 2012-04-26 | 2015-03-31 | Бристол-Майерс Сквибб Компани | Производные имидазотиадиазола в качестве ингибиторов активируемых протеазой рецепторов 4 (par4) для лечения агрегации тромбоцитов |
| EP2855489B1 (en) | 2012-04-26 | 2017-01-04 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| SMT201700457T1 (it) | 2012-04-26 | 2017-11-15 | Bristol Myers Squibb Co | DERlVATI IMIDAZOTIADIAZOLICI E IMIDAZOPIRAZINICI COME INIBITORI DEL RECETTORE ATTIVATO DA PROTEASI 4 (PAR4) PER IL TRATTAMENTO DELL'AGGREGAZIONE PIASTRINICA |
| AU2013265376B2 (en) * | 2012-05-24 | 2017-07-20 | F. Hoffmann-La Roche Ag | 5-amino[1,4]thiazines as BACE 1 inhibitors |
| US9556135B2 (en) | 2012-10-12 | 2017-01-31 | Amgen, Inc. | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
| CA2894919A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | C5,c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors, compositions, and their use |
| CA2902212C (en) | 2013-03-01 | 2020-10-13 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| AU2014225604B2 (en) | 2013-03-08 | 2018-05-17 | Amgen Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| EP2968353B1 (en) | 2013-03-15 | 2018-12-19 | Merck Sharp & Dohme Corp. | C2-azaspiro iminothiazine dioxides as bace inhibitors |
| WO2015017407A1 (en) * | 2013-07-30 | 2015-02-05 | Amgen Inc. | Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta- secretase |
| US9725468B2 (en) | 2013-09-13 | 2017-08-08 | Merck Sharp & Dohme Corp. | C5-spiro iminothiazine dioxides as BACE inhibitors, compositions, and their use |
| US9745324B2 (en) | 2013-12-18 | 2017-08-29 | Merck Sharp & Dohme Corp. | Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use |
| EP3083575B1 (en) | 2013-12-18 | 2021-11-03 | Merck Sharp & Dohme Corp. | C-6 spirocarbocyclic iminothiadiazine dioxides as bace inhibitors, compositions, and their use |
| EP3083644B1 (en) * | 2013-12-20 | 2019-03-13 | F.Hoffmann-La Roche Ag | 5-aryl-1-imino-1-oxo-[1,2,4]thiadiazines |
| US9732088B2 (en) | 2014-06-02 | 2017-08-15 | Merck Sharp & Dohme Corp. | C2-carbocyclic iminothiazine dioxides as BACE inhibitors, compositions, and their use |
| AU2015301028B2 (en) | 2014-08-08 | 2019-09-26 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| US10047098B2 (en) | 2014-11-25 | 2018-08-14 | Merck Sharp & Dohme Corp. | C5-C6-oxacyclic fused iminopyrimidinone compounds as bace inhibitors, compositions, and their use |
| AU2016236402B2 (en) | 2015-03-20 | 2019-08-01 | F. Hoffmann-La Roche Ag | BACE1 inhibitors |
| WO2016172255A1 (en) * | 2015-04-21 | 2016-10-27 | Allgenesis Biotherapeutics, Inc. | Compounds and their use as bace1 inhibitors |
| WO2017024180A1 (en) | 2015-08-06 | 2017-02-09 | Amgen Inc. | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| JP6895424B2 (ja) * | 2015-08-12 | 2021-06-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂａｃｅ１阻害剤 |
| WO2017095759A1 (en) | 2015-12-04 | 2017-06-08 | Merck Sharp & Dohme Corp. | C5-c6-carbocyclic fused iminothiadiazine dioxides as bace inhibitors, compositions, and their use |
| MA54100A (fr) | 2016-12-15 | 2021-10-20 | Amgen Inc | Dérivés de thiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation |
| MX387729B (es) | 2016-12-15 | 2025-03-18 | Amgen Inc | Derivados de dióxido de 1,4-tiazina y dióxido 1,2,4-tiadiazina como inhibidores de beta-secretasa y métodos de uso. |
| CA3047285A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
| US10947223B2 (en) | 2016-12-15 | 2021-03-16 | Amgen Inc. | Substituted oxazines as beta-secretase inhibitors |
| AU2017378316B2 (en) | 2016-12-15 | 2021-04-01 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
| US11629154B2 (en) | 2018-04-27 | 2023-04-18 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective BACE1 inhibitory activity |
| CN109180671A (zh) * | 2018-09-21 | 2019-01-11 | 广东东阳光药业有限公司 | 亚氨基噻二嗪二氧化物衍生物及其用途 |
| BR112022026275A2 (pt) * | 2020-06-30 | 2023-03-14 | 4E Therapeutics Inc | Piridina-1,5-dionas que exibem inibição de mnk e seus métodos de uso |
| CN113105318B (zh) * | 2021-02-23 | 2022-05-20 | 中山大学 | 一种2,2-二氟环丁烷-1-羧酸的制备方法及应用 |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92011A0 (en) | 1988-10-19 | 1990-07-12 | Abbott Lab | Heterocyclic peptide renin inhibitors |
| US5534520A (en) | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
| AU2436792A (en) | 1991-08-16 | 1993-03-16 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
| US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
| EP0980362B1 (de) * | 1997-05-02 | 2006-08-16 | Schering Aktiengesellschaft | Substituierte heterocyclen und deren verwendung in arzneimitteln |
| WO2000051992A1 (en) | 1999-03-04 | 2000-09-08 | E.I. Du Pont De Nemours And Company | Fused bicyclic oxazinone and thiazinone fungicides |
| US7161962B1 (en) | 1999-05-27 | 2007-01-09 | Nuera Communications, Inc. | Method and apparatus for coding modem signals for transmission over voice networks |
| CN1304390C (zh) | 2001-08-03 | 2007-03-14 | 先灵公司 | 新颖的γ—分泌酶抑制剂 |
| US7244764B2 (en) | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| MXPA06001558A (es) | 2003-08-08 | 2006-05-15 | Schering Corp | Inhibidores de amina ciclica bace-1 que poseen un sustituyente heterociclico. |
| EP1660443B1 (en) | 2003-08-08 | 2009-03-04 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
| GB0319463D0 (en) | 2003-08-20 | 2003-09-17 | Givaudan Sa | Compounds |
| US20060034848A1 (en) | 2003-11-07 | 2006-02-16 | Ayae Kinoshita | Methods and compositions for treating Alzheimer's disease |
| EP2335701B1 (en) * | 2003-12-15 | 2012-07-11 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| ES2332659T3 (es) | 2004-06-16 | 2010-02-10 | Wyeth | Derivados de amino-5,5-difenilimidazolona para la inhibicion de beta-secretasa. |
| ATE423121T1 (de) | 2004-06-16 | 2009-03-15 | Wyeth Corp | Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren |
| ATE491693T1 (de) | 2004-07-22 | 2011-01-15 | Schering Corp | Substituierte amide als inhibitoren der beta- sekretase |
| WO2006014944A1 (en) | 2004-07-28 | 2006-02-09 | Schering Corporation | Macrocyclic beta-secretase inhibitors |
| CA2583342A1 (en) | 2004-10-13 | 2006-04-27 | Merck And Co., Inc. | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer's disease |
| US20090221579A1 (en) | 2004-10-15 | 2009-09-03 | Jeffrey Scott Albert | Substituted Amino-Compounds and Uses Thereof |
| JP2008516946A (ja) | 2004-10-15 | 2008-05-22 | アストラゼネカ・アクチエボラーグ | 置換されたアミノ−ピリミドンおよびそれらの使用 |
| US7932275B2 (en) | 2004-10-29 | 2011-04-26 | Merck, Sharp & Dohme Corp. | 2-aminopyridine compounds useful as β-secretase inhibitors for the treatment of alzheimer's disease |
| CN101103034A (zh) | 2005-01-14 | 2008-01-09 | 惠氏公司 | 抑制β-分泌酶的氨基-咪唑酮 |
| DE102005023943A1 (de) | 2005-05-20 | 2006-11-23 | Grünenthal GmbH | Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln |
| US7759354B2 (en) | 2005-06-14 | 2010-07-20 | Schering Corporation | Bicyclic guanidine derivatives as asparyl protease inhibitors, compositions, and uses thereof |
| CN101228163A (zh) | 2005-06-14 | 2008-07-23 | 先灵公司 | 天冬氨酰蛋白酶抑制剂 |
| CA2610828A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
| AR054618A1 (es) | 2005-06-14 | 2007-07-04 | Schering Corp | Compuestos de azetidina y su uso como inhibidores de proteasas |
| AR054510A1 (es) | 2005-06-14 | 2007-06-27 | Schering Corp | Compuestos heterociclicos como inhibidores de aspartil proteasas y composiciones farmaceuticas que los comprenden. |
| JP2008543844A (ja) | 2005-06-14 | 2008-12-04 | シェーリング コーポレイション | アスパルチルプロテアーゼ阻害剤 |
| MX2007016185A (es) | 2005-06-14 | 2008-03-07 | Schering Corp | Inhibidores de aspartil proteasa heterociclicos macrociclicos. |
| EP1896448A1 (en) | 2005-06-30 | 2008-03-12 | Wyeth | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION |
| TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| US8211904B2 (en) | 2005-07-18 | 2012-07-03 | Merck, Sharp & Dohme Corp. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
| KR20080050430A (ko) | 2005-09-26 | 2008-06-05 | 와이어쓰 | 베타-세크레타제 (ｂａｃｅ) 억제제로서아미노-5-[4-(디플루오로메톡시)페닐]-5-페닐이미다졸론화합물 |
| EP2612854B1 (en) | 2005-10-25 | 2015-04-29 | Shionogi&Co., Ltd. | Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors |
| ATE478070T1 (de) | 2005-10-27 | 2010-09-15 | Schering Corp | Heterozyklische aspartyl-proteasehemmer |
| EP1943246A1 (en) | 2005-10-31 | 2008-07-16 | Schering Corporation | Aspartyl protease inhibitors |
| JP2009515949A (ja) | 2005-11-15 | 2009-04-16 | アストラゼネカ・アクチエボラーグ | 新規な２−アミノピリミジノン誘導体およびそれらの使用 |
| CN101360722A (zh) | 2005-11-15 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | 新颖的2-氨基嘧啶衍生物及其用途 |
| TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
| US7897592B2 (en) * | 2005-11-15 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
| WO2007058601A1 (en) | 2005-11-21 | 2007-05-24 | Astrazeneca Ab | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia |
| CN101360737A (zh) | 2005-12-19 | 2009-02-04 | 惠氏公司 | 2-氨基-5-哌啶咪唑酮化合物和其用于β分泌酶调节的用途 |
| AR058381A1 (es) | 2005-12-19 | 2008-01-30 | Astrazeneca Ab | Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica |
| WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
| JP2009532464A (ja) | 2006-04-05 | 2009-09-10 | アストラゼネカ・アクチエボラーグ | ２−アミノピリミジン−４−オン及びＡβ−関連の病理を治療又は予防するためのその使用 |
| EP2032542A2 (en) | 2006-06-12 | 2009-03-11 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| TW200808796A (en) | 2006-06-14 | 2008-02-16 | Astrazeneca Ab | New compounds III |
| TW200815443A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds I |
| TW200815447A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
| TW200815449A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds II |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| TW200817406A (en) | 2006-08-17 | 2008-04-16 | Wyeth Corp | Imidazole amines as inhibitors of β-secretase |
| WO2008063114A1 (en) | 2006-11-20 | 2008-05-29 | Astrazeneca Ab | Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia |
| KR20090090364A (ko) | 2006-12-12 | 2009-08-25 | 쉐링 코포레이션 | 트리사이클릭 환 시스템을 함유하는 아스파르틸 프로테아제 억제제 |
| JP2010512389A (ja) | 2006-12-12 | 2010-04-22 | シェーリング コーポレイション | アスパルチルプロテアーゼ阻害剤 |
| TW200831091A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
| WO2008076043A1 (en) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Novel 2-amino-5,5-diaryl-imidazol-4-ones |
| TW200831484A (en) | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
| CL2008000784A1 (es) | 2007-03-20 | 2008-05-30 | Wyeth Corp | Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co |
| CL2008000791A1 (es) | 2007-03-23 | 2008-05-30 | Wyeth Corp | Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm |
| TW200902526A (en) | 2007-04-24 | 2009-01-16 | Shionogi & Amp Co Ltd | Aminodihydrothiazin derivative substituted with a cyclic group |
| WO2008133273A1 (ja) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | アルツハイマー症治療用医薬組成物 |
| US20110009392A1 (en) | 2007-08-06 | 2011-01-13 | Schering Corporation | Gamma secretase modulators |
| US20090041201A1 (en) | 2007-08-06 | 2009-02-12 | Carestream Health, Inc. | Alignment apparatus for imaging system |
| ES2548774T3 (es) | 2008-01-18 | 2015-10-20 | Eisai R&D Management Co., Ltd. | Derivado de aminodihidrotiazina condensado |
| AU2009217518A1 (en) | 2008-02-28 | 2009-09-03 | Merck Sharp & Dohme Corp. | 2-aminoimidazole beta-secretase inhibitors for the treatment of Alzheimer's disease |
| CL2009000954A1 (es) | 2008-04-22 | 2010-12-31 | Schering Corp | Compuestos derivados de 2-imino-3-metil pirrolo pirimidinona,inhibidores de bace-1; composicion farmaceutica; y su uso para tratar, prevenir y/o retardar el inicio de una patologia de beta-amiloide seleccionada de enfermedad de alzheimer, enfermedad de parkinson, perdida de la memoria, sindrome de down, entre otras. |
| TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| KR20110000749A (ko) | 2008-05-05 | 2011-01-05 | 화이자 인코포레이티드 | 신경변성 질환의 치료용 스피로 피페리딘류 |
| WO2009151098A1 (ja) | 2008-06-13 | 2009-12-17 | 塩野義製薬株式会社 | βセクレターゼ阻害作用を有する含硫黄複素環誘導体 |
| CN102105475B (zh) | 2008-07-28 | 2014-04-09 | 卫材R&D管理有限公司 | 螺氨基二氢噻嗪衍生物 |
| WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
| WO2010021680A2 (en) | 2008-08-19 | 2010-02-25 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
| CA2736130C (en) | 2008-09-11 | 2014-01-14 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use |
| AU2009300836B2 (en) | 2008-09-30 | 2014-02-27 | Eisai R&D Management Co., Ltd. | Novel fused aminodihydrothiazine derivative |
| JPWO2010047372A1 (ja) | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体 |
| WO2010063718A1 (en) | 2008-12-02 | 2010-06-10 | ETH Zürich | Screening assay for metabolic disease therapeuticals |
| US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| GB0912777D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydropyrimidone derivatives |
| GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| AR077328A1 (es) | 2009-07-24 | 2011-08-17 | Novartis Ag | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos |
| US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| WO2011044184A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2011058763A1 (ja) | 2009-11-13 | 2011-05-19 | 塩野義製薬株式会社 | アミノリンカーを有するアミノチアジンまたはアミノオキサジン誘導体 |
| WO2011072064A1 (en) | 2009-12-08 | 2011-06-16 | Array Biopharma Inc. | S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors |
| EP2514747A4 (en) | 2009-12-09 | 2013-05-08 | Shionogi & Co | SUBSTITUTED AMINOTHIAZINE DERIVATIVE |
| WO2011071057A1 (ja) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
| US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
| UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| UA110467C2 (uk) | 2009-12-11 | 2016-01-12 | Шионогі Енд Ко., Лтд. | Похідні оксазину |
| JPWO2011071109A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | アミノ基を有する縮合ヘテロ環化合物 |
| JPWO2011077726A1 (ja) | 2009-12-24 | 2013-05-02 | 塩野義製薬株式会社 | ４−アミノ−１，３−チアジンまたはオキサジン誘導体 |
| CN102712621B (zh) | 2009-12-31 | 2015-03-11 | 诺华股份有限公司 | 吡嗪衍生物及其在治疗神经学障碍中的用途 |
| JP5828848B2 (ja) | 2010-02-24 | 2015-12-09 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | ベータセクレターゼインヒビター |
| WO2011115938A1 (en) | 2010-03-15 | 2011-09-22 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta - secretase modulators |
| AU2011227501B9 (en) | 2010-03-15 | 2013-08-22 | Amgen Inc. | Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as Beta - secretase modulators and their medical use |
| AR080865A1 (es) | 2010-03-31 | 2012-05-16 | Array Biopharma Inc | Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer. |
| WO2011130347A2 (en) | 2010-04-13 | 2011-10-20 | The Johns Hopkins University | Methods for enhancing axonal regeneration |
| WO2011130741A1 (en) | 2010-04-16 | 2011-10-20 | Array Biopharma Inc. | Compounds for treating neurodegenerative diseases |
| US8673894B2 (en) | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
| CN102918036A (zh) | 2010-06-09 | 2013-02-06 | 詹森药业有限公司 | 用作β-分泌酶(BACE)抑制剂的5-氨基-3,6-二氢-1H-吡嗪-2-酮衍生物 |
| AU2011263797B2 (en) * | 2010-06-09 | 2014-06-05 | Janssen Pharmaceutica Nv | 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) |
| DK2483255T3 (da) | 2010-07-13 | 2014-01-20 | Novartis Ag | Oxazinderivater samt deres anvendelse ved behandling af neurologiske lidelser |
| US8815881B2 (en) | 2010-08-09 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds |
| AR083169A1 (es) | 2010-09-24 | 2013-02-06 | Array Biopharma Inc | Compuestos para tratar enfermedades neurodegenerativas |
| EP2634188A4 (en) | 2010-10-29 | 2014-05-07 | Shionogi & Co | FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE |
| CN103261199A (zh) | 2010-10-29 | 2013-08-21 | 盐野义制药株式会社 | 萘啶衍生物 |
| US20120157448A1 (en) | 2010-11-22 | 2012-06-21 | Adam Cook | Compounds for treating neurodegenerative diseases |
| WO2012071279A1 (en) | 2010-11-23 | 2012-05-31 | Amgen Inc. | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use |
| US9242943B2 (en) | 2011-01-18 | 2016-01-26 | Siena Biotech S.P.A. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
| US8399459B2 (en) | 2011-02-02 | 2013-03-19 | Hoffmann-La Roche Inc. | 1,4 oxazines as BACE1 and/or BACE2 inhibitors |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
| CN103596939A (zh) * | 2011-04-13 | 2014-02-19 | 默沙东公司 | 作为bace抑制剂的5-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其应用 |
| MX2013011947A (es) | 2011-04-13 | 2014-01-16 | Merck Sharp & Dohme | Iminotiazinas 5-sustituidas y sus monoxidos y dioxidos como inhibidores de la enzima que encinde la proteina precursora amiloide en el sitio beta, composiciones y su uso. |
| US9079919B2 (en) | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
| JP2012250933A (ja) | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
| KR20140054295A (ko) | 2011-08-22 | 2014-05-08 | 머크 샤프 앤드 돔 코포레이션 | Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도 |
| US8338413B1 (en) | 2012-03-07 | 2012-12-25 | Novartis Ag | Oxazine derivatives and their use in the treatment of neurological disorders |
| AU2013265376B2 (en) * | 2012-05-24 | 2017-07-20 | F. Hoffmann-La Roche Ag | 5-amino[1,4]thiazines as BACE 1 inhibitors |
-
2012
- 2012-08-21 KR KR1020147007258A patent/KR20140054295A/ko not_active Withdrawn
- 2012-08-21 WO PCT/US2012/051687 patent/WO2013028670A1/en not_active Ceased
- 2012-08-21 CA CA2844988A patent/CA2844988A1/en not_active Abandoned
- 2012-08-21 CN CN201280051313.9A patent/CN103874496A/zh active Pending
- 2012-08-21 RU RU2014111055/04A patent/RU2014111055A/ru not_active Application Discontinuation
- 2012-08-21 BR BR112014004181A patent/BR112014004181A2/pt unknown
- 2012-08-21 MX MX2014002113A patent/MX2014002113A/es unknown
- 2012-08-21 AU AU2012298983A patent/AU2012298983A1/en not_active Abandoned
- 2012-08-21 EP EP12825781.3A patent/EP2747769B1/en active Active
- 2012-08-21 US US14/240,215 patent/US9181236B2/en active Active
- 2012-08-21 JP JP2014527238A patent/JP2014524472A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014514302A5 (enExample) | ||
| RU2014111055A (ru) | 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение | |
| RU2013150349A (ru) | 5-замещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов васе, содержащие их композиции и их применение | |
| RU2445957C2 (ru) | Аналоги тиазолидиндиона | |
| JP5934403B2 (ja) | ５，６−ジヒドロ−１ｈ−ピリジン−２−オン化合物 | |
| RU2317294C2 (ru) | (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора | |
| JP2007519649A5 (enExample) | ||
| JP2019031560A5 (enExample) | ||
| RU2011129856A (ru) | Схема приема агониста рецептора s1p | |
| JP2011523412A5 (enExample) | ||
| JP2010524932A5 (enExample) | ||
| JP2009520685A5 (enExample) | ||
| JP2007269797A5 (enExample) | ||
| RU2016137832A (ru) | Соединения для лечения опосредованных комплементом нарушений | |
| JP2013510825A5 (enExample) | ||
| RU2018133158A (ru) | Способы применения агонистов fxr | |
| JP2009504764A5 (enExample) | ||
| JP2015515961A5 (enExample) | ||
| JP2022500392A5 (enExample) | ||
| JP2015524450A5 (enExample) | ||
| JP2020097596A5 (enExample) | ||
| FI3487505T3 (fi) | Diaminofenotiatsiinien antaminen ja annostus | |
| KR20170131644A (ko) | 인단 아세트산 유도체를 사용한 간 질환의 치료 방법 | |
| JP2009515949A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения |